Engineering a Brighter Future : The Evolving Role of the Pharmacist in the Era of the HeartMate 3
Continuous-flow left-ventricular assist devices (CF-LVADs) are an option for patients with end-stage heart failure requiring durable mechanical circulatory support. Two of the older-generation CF-LVADs have been associated with multiple device-related complications, including bleeding and thrombosis. The newest generation CF-LVAD, the HeartMate 3, was engineered specifically to prevent device-related thrombosis. As more data enhance our understanding of the burden of bleeding and thrombotic adverse events, patients with durable mechanical circulatory support may require less-aggressive antithrombotic therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
The Annals of pharmacotherapy - 53(2019), 4 vom: 01. Apr., Seite 430-433 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ciolek, Alana M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulation |
|---|
| Anmerkungen: |
Date Completed 26.02.2020 Date Revised 26.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1060028018813371 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29037362X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29037362X | ||
| 003 | DE-627 | ||
| 005 | 20231225064605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1060028018813371 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0967.xml |
| 035 | |a (DE-627)NLM29037362X | ||
| 035 | |a (NLM)30404537 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ciolek, Alana M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineering a Brighter Future |b The Evolving Role of the Pharmacist in the Era of the HeartMate 3 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2020 | ||
| 500 | |a Date Revised 26.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Continuous-flow left-ventricular assist devices (CF-LVADs) are an option for patients with end-stage heart failure requiring durable mechanical circulatory support. Two of the older-generation CF-LVADs have been associated with multiple device-related complications, including bleeding and thrombosis. The newest generation CF-LVAD, the HeartMate 3, was engineered specifically to prevent device-related thrombosis. As more data enhance our understanding of the burden of bleeding and thrombotic adverse events, patients with durable mechanical circulatory support may require less-aggressive antithrombotic therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HeartMate 3 | |
| 650 | 4 | |a anticoagulation | |
| 650 | 4 | |a hemocompatibility | |
| 650 | 4 | |a left-ventricular assist device | |
| 700 | 1 | |a Littlefield, Audrey J |e verfasserin |4 aut | |
| 700 | 1 | |a Jennings, Douglas L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Annals of pharmacotherapy |d 1993 |g 53(2019), 4 vom: 01. Apr., Seite 430-433 |w (DE-627)NLM012749435 |x 1060-0280 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2019 |g number:4 |g day:01 |g month:04 |g pages:430-433 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1060028018813371 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2019 |e 4 |b 01 |c 04 |h 430-433 | ||